Abstract

DO.14.13

24 Gy brachytherapy delivered following a limited vitrectomy approach combined with Lucentis^®

Foja C., Wiedemann P.
Universitäts-Augenklinik Leipzig

Objective: Epiretinal brachytherapy is being studied in a pivotal randomized controlled clinical trial (CABERNET trial, NeoVista^®) exploring the concomitant use of radiotherapy with Lucentis^® in neovascular AMD. Lucentis® is a monoclonal antibody to vascular endothelial growth factor used to treat neovascular AMD but intensive patient review and retreatment are needed to achieve the functional outcomes obtained in the ANCHOR and MARINA pivotal clinical trials. Reducing the need for repeated monthly review and multiple injections would reduce the burden on health care systems, provide potential gains through reduced adverse events, and have an impact on the quality of life of the patient and caregiver.
Methods: The surgical technique of delivering 24 Gy beta radiation using a novel medical device in an epiretinal approach through a vitrectomy along with administration of Lucentis^® at the time of surgery is demonstrated.
Results: Surgical details are demonstrated.
Conclusions: Combining focal radiotherapy with concomitant delivery of Lucentis^® may reduce the need for multiple dosing and provide anatomical changes to the lesion composition including a decrease in lesion size and more specifically reduction in fibrovascular scar formation.

Copyright: Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.